Back to top

Analyst Blog

The recent US Food and Drug Administration (“FDA”) 510(k) clearance for Affinity Fusion oxygenation system has enhanced the structural heart business of medical devices major – Medtronic, Inc. (MDT - Analyst Report). The company also announced the first US clinical use of this new oxygenation system. Notably, last September, the company gained CE Mark for this system in Europe.

According to Medtronic, this new system, which combines several advanced features, oxygenates and removes carbon dioxide from blood during several open-heart surgical procedures. The company claims that these new features potentially reduce the risk of stroke, preventing the entry of air bubbles in blood during the surgery procedure. According to the company, this system can be helpful for hospitals, which are focusing on implementation of patient blood management programs and other initiatives.

With a number of heart patients undergoing cardiac surgery annually, Medtronic remains hopeful about the greater adoption of this oxygenation system among physicians and hospitals. The company encouragingly noted that, this year, there would be about 1 million cases of cardiopulmonary bypass worldwide. The process has already included the collaboration between the company and more than 500 perfusionists globally.


Medtronic’s consistent expansion of its portfolio via approvals in the domestic and international market is encouraging. With the FDA approval for Affinity Fusion oxygenation system, the company extended its structural heart portfolio. Medtronic’s focus on the structural heart business is likely to deliver positive results, as substantial adoption of newer products should leverage the top line.

According to the company, the structural heart business is a high-focus franchise in the emerging markets, especially in China. Notably, Medtronic’s peer in the structural heart business Edwards Lifesciences (EW - Analyst Report) is also committed to meaningful portfolio expansion.

New product launches are expected to contribute at least $200 million in fiscal 2014 for Medtronic. However, unfavorable currency movement, tough competitive landscape and global economic uncertainties keep us on the sidelines. The stock carries a Zacks Rank #3 (Hold). However, other stocks in the medical device sector, carrying a Zacks Rank #1 (Strong Buy), such as Medical Action Industries Inc. and Cyberonics Inc. (CYBX - Analyst Report) appear impressive.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.23 +7.10%
CENTURY ALU… CENX 26.54 +6.24%
TESLA MOTOR… TSLA 282.12 +4.61%
BAIDU ADS BIDU 222.77 +3.85%
RTI SURGICA… RTIX 5.51 +3.77%